CAESAREA, Israel - IceCure Medical Ltd. (NASDAQ:ICCM), a company specializing in cryoablation technologies, announced today that it has received a Notice of Allowance from the Japan Patent Office for a patent titled "Cryogen Flow Control".
This patent, which is expected to remain in effect until 2042, is part of IceCure's strategy to enhance the precision and effectiveness of cryoablation procedures, a minimally invasive method to destroy tumors by freezing.
The ProSense® System, developed by IceCure, utilizes liquid nitrogen to freeze and eradicate both benign and malignant tumors, including those found in the breast, kidney, lung, and liver. The system is designed for ease of use and transportability, enabling quick office-based procedures for breast tumors, thereby potentially reducing recovery times, pain, and surgical risks for patients.
The newly allowed patent focuses on the regulation of cryogen flow based on sensor data, ensuring that the desired temperature is consistently maintained at the tip of catheters and probes during cryoablation.
This control is critical for the safety of surrounding tissues and the overall success of the procedure. Advanced features of the system may include support for navigation and mapping within the patient's body, expanding the potential applications of the technology.
Eyal Shamir, CEO of IceCure, expressed confidence that the new patent will play a significant role in advancing the field of cryoablation by allowing for more precise navigation and mapping, which could lead to broader clinical applications. The company's partnership with Terumo, its distributor in Japan, is expected to strengthen IceCure's presence in the Japanese market.
The patent is still pending approval in other major markets, including the European Union and the United States. IceCure's intellectual property portfolio now includes 42 issued and allowed patents, reflecting its commitment to innovation in the field of cryoablation technology.
The information in this article is based on a press release statement from IceCure Medical.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.